KaloCyte is a pre-clinical biotech therapeutic startup company developing ErythroMer, a bioengineered artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage and is envisioned for pre-hospital treatment of traumatic hemorrhage when stored blood is unavailable, undesirable or in short supply. Blood loss is the leading cause of preventable death due to trauma, responsible for over 30,000 preventable deaths each year in the US alone. ErythroMer is a universal option for all blood types and has potential for accelerated regulatory pathways. We’ve demonstrated proof of concept, safety and efficacy in animal models (mice and rabbits) and are completing advanced shock models and initiating PK studies while we scale up our fabrication and lyophilization. KaloCyte is supported by nearly $9M in non-dilutive federal grant awards (NIH and DoD) and $2.3M of investor funding. Seeking investors for upcoming raise to fund IND submission through Phase I trials.
KaloCyte, Inc. is presenting as part of the NIH Innovation Zone.